Search
Dexketoprofen
go.drugbank.com/drugs/DB09214ApprovedInvestigationalWithdrawnIt has analgesic, antipyretic and anti-inflammatory properties [L1298].
Mixtures: LEODEX PLUS 50 MG/8 MG FILM KAPLI TABLET,10 TABLET, LEODEX PLUS 25 MG/8 MG FILM KAPLI TABLET,10 TABLETCategories: Non COX-2 selective NSAIDSSimethicone
go.drugbank.com/drugs/DB09512ApprovedInvestigational[A228308] It has a favourable safety profile as it is not systemically absorbed.[A228308] Simethicone has been in use since the 1940s[A228303] but was granted FDA approval in 1952.[A228308] … Simethicone is a silicon based surfactant that decreases the surface tension of gastrointestinal gas bubbles to facilitate their elimination.
Mixtures: PANLIPAZ 170/80 MG ENTERİK KAPLI FİLM TABLET, 20 ADET, TRIMEBUTINA 200 MG + SIMETICONA 120 MGProducts: METSIL FORT 80 MG ÇIĞNEME TABLETI, 20 ADET, FLATOGAST 140 MG YUMUŞAK KAPSÜL, 20 KAPSÜLAmlodipine
go.drugbank.com/drugs/DB00381ApprovedInvestigationalAmlodipine has antioxidant properties and an ability to enhance the production of nitric oxide (NO), an important vasodilator that decreases blood pressure [A175321].
Synonyms: Amlodipine free base, (RS)-3-ethyl 5-methyl 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-6-methyl-1,4-dihydropyridine-3,5-dicarboxylateInternational brands: Amlodipin-Mepha 5/10Buprenorphine
go.drugbank.com/drugs/DB00921ApprovedIllicitInvestigationalVet approved[A186263,A186266,A186269] Buprenorphine acts as a partial mu-opioid receptor agonist with a high affinity for the receptor, but lower intrinsic activity compared to other full mu-opioid agonists such … Buprenorphine is a weak partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist used for the treatment of severe pain.
Mixtures: Bupensan Duo 4 mg/1 mg-Sublingualtabletten, SUBOXONE 8 MG/2 MG DILALTI TABLET, 28 ADETSynonyms: 2-[3-cyclopropylmethyl-11-hydroxy-15-methoxy-(14R)-13-oxa-3-azahexacyclo[13.2.2.12,8.01,6.06,14.07,12]icosa-7,9,11-trien-16-yl]-3,3-dimethyl-2-butanol, 21-cyclopropyl-7α-[(S)-1-hydroxy-1,2,2-trimethylpropyl]-6,14-endo-ethano-6,7,8,14-tetrahydrooripavineTorasemide
go.drugbank.com/drugs/DB00214ApprovedInvestigational[A174463] Structurally, it is a pyridine-sulfonylurea used as an antihypertensive agent.[A319] Torasemide was first approved for clinical use by the FDA in 1993.[L5257]
Synonyms: 1-Isopropyl-3-((4-m-toluidino-3-pyridyl)sulfonyl)urea, N-(((1-Methylethyl)amino)carbonyl)-4-((3-methylphenyl)amino)-3-pyridinesulfonamideCategories: Heterocyclic Compounds, 1-RingLactulose
go.drugbank.com/drugs/DB00581ApprovedInvestigationaland its first clinical use for treating PSE was not until 1966. … Lactulose is a synthetic disaccharide derivative of lactose that is most commonly used as a laxative agent despite also being formally indicated to serve as an adjunct therapy in treating portal-systemic
Products: Laevolac 10 g/15 ml Lösung zum Einnehmen, LaevoGo Pflaumenaroma 10 g/15 ml Lösung zum EinnehmenCisplatin
go.drugbank.com/drugs/DB00515ApprovedInvestigationalIt was the first member of its class, which now also includes carboplatin and oxaliplatin.
Synonyms: (SP-4-2)-DIAMMINEDICHLOROPLATINUM, INT-230-6 COMPONENT CISPLATINProducts: CISPLATINO 10 MG/20 ML, CISPLATINO 10 MG / 20 ML.Cytarabine
go.drugbank.com/drugs/DB00987ApprovedInvestigationalIt also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472)
Categories: Heterocyclic Compounds, 1-RingSynonyms: 4-Amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone, 1-beta-D-ArabinofuranosylcytosineIpratropium
go.drugbank.com/drugs/DB00332ApprovedInvestigational] was approved in 1996. … [A176957] Ipratropium as a therapeutic agent was developed by Boehringer Ingelheim and its first monotherapy product was FDA approved in 1986, while the combination product of ipratropium and [albuterol
Mixtures: COMBIVENT OLCULU DOZ INHALATORLU AEROSOL 10 ML, PRALAS 2,5 MG+0,5 MG/2,5 ML NEBÜLİZASYON ÇÖZELTİSİ, 20 ADETProducts: IPRACORT 20 MCG AEROSOL İNHALER, 1 ADET, ATROVENT 500 MG /2MLAmbroxol
go.drugbank.com/drugs/DB06742ApprovedInvestigationalSurfactants acts as an anti-glue factor by reducing the adhesion of mucus to the bronchial wall, in improving its transport and in providing protection against infection and irritating agents.
Mixtures: AMBROXOL 15 MG+ CLENBUTEROL 10 MCG /5 ML, AMBROXOL 150 MG / 100 ML + CLENBUTEROL 0.1 MG / 100 ML SOLUCIÓN ORAL NIÑOSCategories: Selective Beta 2-adrenergic Agonists